Clinical implications of immunity to oncogenic viruses.
D000914:Antibodies, Viral / Q000032:analysis; D000956:Antigens, Viral / Q000032:analysis; D002051:Burkitt Lymphoma / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control; D004854:Herpesvirus 4, Human / Q000276:immunology; D007111:Immunity, Cellular; D007167:Immunotherapy; D007244:Infectious Mononucleosis / Q000276:immunology; D009303:Nasopharyngeal Neoplasms / Q000382:microbiology; D009369:Neoplasms / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control / Q000628:therapy / Q000635:transmission; D009858:Oncogenic Viruses / Q000276:immunology*; D012698:Serologic Tests; D018139:Simplexvirus / Q000276:immunology; D014612:Vaccines
D000914:Antibodies, Viral; D000956:Antigens, Viral; D014612:Vaccines